Here are four things to know.
1. The new treatment combines Vertex’s previously approved drug Kalydeco with another medicine called tezacaftor to treat cystic fibrosis.
2. The new combination treatment, which will be sold under the brand name Symdeko, is expected to form the backbone for a triple combination in future years.
3. The current medications can help about 45 percent of the CF population. Vertex believes a triple combination medicine could end up helping 90 percent of the population.
4. Symdeko is approved for cystic fibrosis patients 12 years and older who have at least one mutation responsive to tezacaftor or two copies of the F508del gene mutation.
More articles on supply chain:
Pfizer’s opioid-filled syringes hit another manufacturing snag: 6 things to know
Amazon pushes to become a major hospital supplier: 7 things to know
Walgreens is reportedly in talks to purchase AmerisourceBergen: 7 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
